Search

Your search keyword '"Mcstea, Megan"' showing total 18 results
Start Over Author "Mcstea, Megan"
18 results on '"Mcstea, Megan"'

2. The clinicopathological features of thrombosis with thrombocytopenia syndrome following ChAdOx1-S (AZD1222) vaccination and case outcomes in Australia: a population-based study

Author

Tran, Huyen A., Deng, Lucy, Wood, Nicholas, Choi, Philip, Singleton, Sally, Clarke, Lisa, Khanlari, Sarah, Maitland-Scott, Isis, Bird, Robert, Brown, Scott, Manoharan, Bavahuna, Tan, Chee Wee, Gold, Michael, Hissaria, Pravin, Melody, Shannon, Chunilal S, Sanjeev D., Buttery, Jim, Clothier, Hazel, Crawford, Nigel W., Phuong, Linny, Pepperell, Dominic, Effler, Paul, Parker, Claire, Carter, Nicola, Macartney, Kristine, McStea, Megan, Miller, Todd, Nissen, Michael, Larter, Claire, Kay, Elspeth, and Chen, Vivien M.

Published
2023
Full Text
View/download PDF

9. A cluster-randomized trial of workplace ergonomics and neck-specific exercise versus ergonomics and health promotion for office workers to manage neck pain—a secondary outcome analysis

Author

Johnston, Venerina, primary, Chen, Xiaoqi, additional, Welch, Alyssa, additional, Sjøgaard, Gisela, additional, Comans, Tracy A, additional, McStea, Megan, additional, Straker, Leon, additional, Melloh, Markus, additional, Pereira, Michelle, additional, and O'Leary, Shaun, additional

Published
2020
Full Text
View/download PDF

11. Outcomes of ESKD patients due to MN v1

Author

Yang, Wenling, primary, Bose, Bhadran, additional, Zhang, Lei, additional, Mcstea, Megan, additional, Cho, Yeoungjee, additional, Fahim, Magid, additional, M. Hawley, Carmel, additional, M. Pascoe, Elaine, additional, and W. Johnson, David, additional

Published
2019
Full Text
View/download PDF

12. Assessment of sarcopenia in virally suppressed HIV-infected Asians receiving treatment

Author

Abdul Aziz, Siti Azdiah, primary, Mcstea, Megan, additional, Ahmad Bashah, Nor Syuhada, additional, Chong, Meng Li, additional, Ponnampalavanar, Sasheela, additional, Syed Omar, Sharifah Faridah, additional, Sulaiman, Helmi, additional, Azwa, Iskandar, additional, Tan, Maw Pin, additional, Kamarulzaman, Adeeba, additional, Rajasuriar, Reena, additional, and Kamaruzzaman, Shahrul Bahyah, additional

Published
2018
Full Text
View/download PDF

13. HIV/Human herpesvirus co-infections: Impact on tryptophan-kynurenine pathway and immune reconstitution

Author

Yap, Siew Hwei, primary, Abdullah, Noor Kamila, additional, McStea, Megan, additional, Takayama, Kozo, additional, Chong, Meng Li, additional, Crisci, Elisa, additional, Larsson, Marie, additional, Azwa, Iskandar, additional, Kamarulzaman, Adeeba, additional, Leong, Kok Hoong, additional, Woo, Yin Ling, additional, and Rajasuriar, Reena, additional

Published
2017
Full Text
View/download PDF

14. Prevalence, risk factors and health outcomes associated with polypharmacy among urban community-dwelling older adults in multi-ethnic Malaysia

Author

Lim, Li Min, primary, McStea, Megan, additional, Chung, Wen Wei, additional, Nor Azmi, Nuruljannah, additional, Abdul Aziz, Siti Azdiah, additional, Alwi, Syireen, additional, Kamarulzaman, Adeeba, additional, Kamaruzzaman, Shahrul Bahyah, additional, Chua, Siew Siang, additional, and Rajasuriar, Reena, additional

Published
2017
Full Text
View/download PDF

15. HIV/Human herpesvirus co-infections: Impact on tryptophan-kynurenine pathway and immune reconstitution

Author

Hwei Yap, Siew, Kamila Abdullah, Noor, McStea, Megan, Takayama, Kozo, Li Chong, Meng, Crisci, Elisa, Larsson, Marie, Azwa, Iskandar, Kamarulzaman, Adeeba, Hoong Leong, Kok, Ling Woo, Yin, Rajasuriar, Reena, Hwei Yap, Siew, Kamila Abdullah, Noor, McStea, Megan, Takayama, Kozo, Li Chong, Meng, Crisci, Elisa, Larsson, Marie, Azwa, Iskandar, Kamarulzaman, Adeeba, Hoong Leong, Kok, Ling Woo, Yin, and Rajasuriar, Reena

Abstract

Background Co-infections with human herpesvirus (HHV) have been associated with residual chronic inflammation in antiretroviral (ART)-treated human immunodeficiency virus (HIV)-infected individuals. However, the role of HHV in modulating the tryptophan-kynurenine pathway and clinical outcomes in HIV-infected individuals is poorly understood. Thus, we investigated the seroprevalence of four common HHVs among treated HIV-infected participants and their impact on kynurenine/tryptophan (K/T) ratio and long-term CD4 T-cell recovery in HIV/HHV co-infected participants. Method In this cross-sectional study, HIV-infected participants receiving suppressive ART for a minimum of 12 months were recruited from the University Malaya Medical Centre (UMMC), Malaysia. Stored plasma was analyzed for CMV, VZV, HSV-1 and HSV-2 IgG antibody levels, immune activation markers (interleukin-6, interferon-gamma, neopterin and sCD14), kynurenine and tryptophan concentrations. The influence of the number of HHV co-infection and K/T ratio on CD4 T-cell recovery was assessed using multivariate Poisson regression. Results A total of 232 HIV-infected participants were recruited and all participants were seropositive for at least one HHV; 96.1% with CMV, 86.6% with VZV, 70.7% with HSV-1 and 53.9% with HSV-2. K/T ratio had a significant positive correlation with CMV (rho = 0.205, p = 0.002), VZV (rho = 0.173, p = 0.009) and a tendency with HSV-2 (rho = 0.120, p = 0.070), with CMV antibody titer demonstrating the strongest modulating effect on K/T ratio among the four HHVs assessed in SOM analysis. In multivariate analysis, higher K/T ratio (p = 0.03) and increasing number of HHV co-infections (pamp;lt;0.001) were independently associated with poorer CD4 T-cell recovery following 12 months of ART initiation. Conclusion Multiple HHV co-infections are common among ART-treated HIV-infected participants in the developing country setting and associated with persistent immune activation and poorer CD4 T-ce, Funding Agencies|High Impact Research/Ministry of Higher Education, Malaysia (HIR/MOHE) [H-20001-E000001]; UMRG [RP029-14HTM]; University of Malaya [PG164-2015B]; Swedish Research Council; Swedish International Development Cooperation Agency; SIDA SARC; VINNMER for Vinnova [A152731]

Published
2017
Full Text
View/download PDF

17. Predictors of new‐onset chronic kidney disease in patients managed surgically for T1a renal cell carcinoma: An Australian population‐based analysis.

Author

Ahn, Thomas, Ellis, Robert J., White, Victoria M., Bolton, Damien M., Coory, Michael D., Davis, Ian D., Francis, Ross S., Giles, Graham G., Gobe, Glenda C., Hawley, Carmel M., Johnson, David W., Marco, David J. T., McStea, Megan, Neale, Rachel E., Pascoe, Elaine M., Wood, Simon T., Jordan, Susan J., and the IMPROVE investigators

Published
2018
Full Text
View/download PDF

18. End-Stage Kidney Disease following Surgical Management of Kidney Cancer.

Author

Ellis RJ, Edey DP, Del Vecchio SJ, McStea M, Campbell SB, Hawley CM, Johnson DW, Morais C, Jordan SJ, Francis RS, Wood ST, and Gobe GC

Subjects
Age Factors, Aged, Diabetes Mellitus epidemiology, Female, Health Status, Humans, Incidence, Length of Stay, Male, Middle Aged, Nephrectomy, Poverty, Queensland epidemiology, Registries, Risk Factors, Sex Factors, Kidney Failure, Chronic epidemiology, Kidney Neoplasms surgery, Postoperative Complications epidemiology
Abstract

Background and Objectives: We investigated the incidence of ESKD after surgical management of kidney cancer in the Australian state of Queensland, and described patterns in the initiation of kidney replacement therapy resulting from kidney cancer across Australia., Design, Setting, Participants, & Measurements: All newly diagnosed cases of kidney cancer in the Australian state of Queensland between January of 2009 and December of 2014 were ascertained through the Queensland Cancer Registry. There were 2739 patients included in our analysis. Patients who developed ESKD were identified using international classification of disease-10-coded hospital administrative data. Incidence rate and 3-year cumulative incidence were calculated, and multivariable Cox proportional hazards models were used to identify factors associated with ESKD. Additional descriptive analysis was undertaken of Australian population data., Results: The incidence rate of ESKD in all patients was 4.9 (95% confidence interval [95% CI], 3.9 to 6.2) per 1000 patient-years. The 3-year cumulative incidence was 1.7%, 1.9%, and 1.0% for all patients, and patients managed with radical or partial nephrectomy, respectively. Apart from preoperative kidney disease, exposures associated with increased ESKD risk were age≥65 years (adjusted hazard ratio [aHR], 2.0; 95% CI, 1.2 to 3.2), male sex (aHR, 2.3; 95% CI, 1.3 to 4.3), preoperative diabetes (aHR, 1.8; 95% CI, 1.0 to 3.3), American Society of Anesthesiologists classification ≥3 (aHR, 4.0; 95% CI, 2.2 to 7.4), socioeconomic disadvantage (aHR, 1.6; 95% CI, 0.9 to 2.7), and postoperative length of hospitalization ≥6 days (aHR, 2.1; 95% CI, 1.4 to 3.0). Australia-wide trends indicate that the rate of kidney replacement therapy after oncologic nephrectomy doubled between 1995 and 2015, from 0.3 to 0.6 per 100,000 per year., Conclusions: In Queensland between 2009 and 2014, one in 53 patients managed with radical nephrectomy and one in 100 patients managed with partial nephrectomy developed ESKD within 3 years of surgery., Podcast: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2018_09_28_CJASNPodcast_18_1_.mp3., (Copyright © 2018 by the American Society of Nephrology.)

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results